Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma
NCT04209686Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jul 2020
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Paclitaxel Micelles for Injection, olaparib, pembrolizumab in gastric adenocarcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Jul 2020; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT04209686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209686.